Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in J Immunother

Retrieve available abstracts of 36 articles:
HTML format
Text format



Single Articles


    April 2018
  1. MEHTA GU, Malekzadeh P, Shelton T, White DE, et al
    Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
    J Immunother. 2018 Apr 18. doi: 10.1097/CJI.0000000000000223.
    PubMed     Text format     Abstract available


    February 2018
  2. TANDON P, Bourassa-Blanchette S, Bishay K, Parlow S, et al
    The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
    J Immunother. 2018 Feb 2. doi: 10.1097/CJI.0000000000000213.
    PubMed     Text format     Abstract available


    January 2018
  3. GORDY JT, Luo K, Francica B, Drake C, et al
    Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3alpha-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.
    J Immunother. 2018 Jan 12. doi: 10.1097/CJI.0000000000000212.
    PubMed     Text format     Abstract available


  4. ANASTASOPOULOU A, Papaxoinis G, Diamantopoulos P, Christofidou E, et al
    Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
    J Immunother. 2018 Jan 5. doi: 10.1097/CJI.0000000000000210.
    PubMed     Text format     Abstract available


    December 2017
  5. COWEY CL, Liu FX, Black-Shinn J, Stevinson K, et al
    Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
    J Immunother. 2017 Dec 15. doi: 10.1097/CJI.0000000000000204.
    PubMed     Text format     Abstract available


    September 2017
  6. ZECCHINI JM, Kim S, Yum K, Friedlander P, et al
    Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
    J Immunother. 2017 Sep 18. doi: 10.1097/CJI.0000000000000184.
    PubMed     Text format     Abstract available


    July 2017
  7. REDDY SB, Possick JD, Kluger HM, Galan A, et al
    Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    J Immunother. 2017 Jul 21. doi: 10.1097/CJI.0000000000000181.
    PubMed     Text format     Abstract available


    June 2017
  8. PUSHKAREVSKAYA A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, et al
    Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
    J Immunother. 2017 Jun 9. doi: 10.1097/CJI.0000000000000178.
    PubMed     Text format     Abstract available


  9. KELLY WU W, Broman KK, Brownie ER, Kauffmann RM, et al
    Ipilimumab-induced Guillain-Barre Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
    J Immunother. 2017;40:196-199.
    PubMed     Text format     Abstract available


  10. YU G, Moudgil T, Cui Z, Mou Y, et al
    Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
    J Immunother. 2017;40:155-163.
    PubMed     Text format     Abstract available


    May 2017
  11. DIAMANTOPOULOS PT, Tsatsou K, Benopoulou O, Anastasopoulou A, et al
    Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
    J Immunother. 2017 May 11. doi: 10.1097/CJI.0000000000000172.
    PubMed     Text format     Abstract available


    February 2017
  12. DAGOGO-JACK I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, et al
    A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
    J Immunother. 2017 Feb 17. doi: 10.1097/CJI.0000000000000159.
    PubMed     Text format     Abstract available


  13. BRICOUT M, Petre A, Amini-Adle M, Bezza W, et al
    Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
    J Immunother. 2017;40:77-82.
    PubMed     Text format     Abstract available


    January 2017
  14. DAY F, Kumar M, Fenton L, Gedye C, et al
    Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    J Immunother. 2017;40:36-38.
    PubMed     Text format     Abstract available


    November 2016
  15. BRIGHT R, Coventry BJ, Eardley-Harris N, Briggs N, et al
    Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  16. JOHNSON DB, Pectasides E, Feld E, Ye F, et al
    Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  17. DILLER ML, Kudchadkar RR, Delman KA, Lawson DH, et al
    Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients.
    J Immunother. 2016;39:355-366.
    PubMed     Text format     Abstract available


  18. TAHTINEN S, Blattner C, Vaha-Koskela M, Saha D, et al
    T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFalpha Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    J Immunother. 2016;39:343-354.
    PubMed     Text format     Abstract available


    September 2016
  19. MA Q, Zhou D, DeLyria ES, Wen X, et al
    Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  20. DIEM S, Keller F, Ruesch R, Maillard SA, et al
    Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  21. KROPP LM, De Los Santos JF, McKee SB, Conry RM, et al
    Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    August 2016
  22. ENGELSTEIN R, Merims S, Eisenberg G, Cohen J, et al
    Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    July 2016
  23. WALKER J, Smylie A, Smylie M
    An Association Between Glatiramer Acetate and Malignant Melanoma.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    May 2016
  24. BOUDEWIJNS S, Westdorp H, Koornstra RH, Aarntzen EH, et al
    Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    April 2016
  25. NAYAR N, Briscoe K, Fernandez Penas P
    Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
    J Immunother. 2016;39:149-52.
    PubMed     Text format     Abstract available


    March 2016
  26. MAUL LV, Weichenthal M, Kahler KC, Hauschild A, et al
    Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  27. HSIEH CT, Luo YH, Chien CS, Wu CH, et al
    Induced Pluripotent Stem Cell-conditioned Medium Suppressed Melanoma Tumorigenicity Through the Enhancement of Natural-Killer Cellular Immunity.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    January 2016
  28. ZHANG M, Graor H, Yan L, Kim J, et al
    Identification of Melanoma-reactive CD4+ T-Cell Subsets From Human Melanoma Draining Lymph Nodes.
    J Immunother. 2016;39:15-26.
    PubMed     Text format     Abstract available


  29. PARK TS, Groh EM, Patel K, Kerkar SP, et al
    Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
    J Immunother. 2016;39:1-7.
    PubMed     Text format     Abstract available


    November 2015
  30. KIBBI N, Ariyan S, Faries M, Choi JN, et al
    Treatment of In-Transit Melanoma With Intralesional Bacillus Calmette-Guerin (BCG) and Topical Imiquimod 5% Cream: A Report of 3 Cases.
    J Immunother. 2015;38:371-375.
    PubMed     Text format     Abstract available


  31. DUPUIS ML, Fiori V, Soriani A, Ricci B, et al
    The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer Cell Cytotoxicity Against Melanoma Cell Lines In Vitro.
    J Immunother. 2015;38:357-370.
    PubMed     Text format     Abstract available


    July 2015
  32. ZHANG M, Graor H, Visioni A, Strohl M, et al
    T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft Model.
    J Immunother. 2015;38:229-38.
    PubMed     Text format     Abstract available


    June 2015
  33. RANGANATH HA, Panella TJ
    Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma.
    J Immunother. 2015;38:211.
    PubMed     Text format     Abstract available


    May 2015
  34. LUDLOW SP, Kay N
    Delayed dermatologic hypersensitivity reaction secondary to ipilimumab.
    J Immunother. 2015;38:165-6.
    PubMed     Text format     Abstract available


    February 2015
  35. THAIPISUTTIKUL I, Chapman P, Avila EK
    Peripheral neuropathy associated with ipilimumab: a report of 2 cases.
    J Immunother. 2015;38:77-9.
    PubMed     Text format     Abstract available


    January 2015
  36. GARGETT T, Fraser CK, Dotti G, Yvon ES, et al
    BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
    J Immunother. 2015;38:12-23.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: